Randall L Carpenter
Overview
Explore the profile of Randall L Carpenter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
883
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campbell K, Neul J, Lieberman D, Berry-Kravis E, Benke T, Fu C, et al.
J Neurodev Disord
. 2025 Jan;
17(1):4.
PMID: 39856538
Background: Preclinical studies and anecdotal case reports support the potential therapeutic benefit of low-dose oral ketamine as a treatment of clinical symptoms in Rett syndrome (RTT); however, no controlled studies...
2.
Reeve B, Lucas N, Chen D, McFatrich M, Jones H, Gordon K, et al.
Eur J Paediatr Neurol
. 2023 Aug;
46:74-81.
PMID: 37536121
Purpose: The study goal was to validate the Observer-Reported Communication Ability (ORCA) measure for use with females with Rett Syndrome (RTT). Methods: Qualitative interviews, including concept elicitation and cognitive interviewing...
3.
Saliva MicroRNA Differentiates Children With Autism From Peers With Typical and Atypical Development
Hicks S, Carpenter R, Wagner K, Pauley R, Barros M, Tierney-Aves C, et al.
J Am Acad Child Adolesc Psychiatry
. 2019 Mar;
59(2):296-308.
PMID: 30926572
Objective: Clinical diagnosis of autism spectrum disorder (ASD) relies on time-consuming subjective assessments. The primary purpose of this study was to investigate the utility of salivary microRNAs for differentiating children...
4.
Hicks S, Rajan A, Wagner K, Barns S, Carpenter R, Middleton F
Front Genet
. 2018 Nov;
9:534.
PMID: 30473705
The diagnosis of autism spectrum disorder (ASD) relies on behavioral assessment. Efforts to define biomarkers of ASD have not resulted in an objective, reliable test. Studies of RNA levels in...
5.
Berry-Kravis E, Lindemann L, Jonch A, Apostol G, Bear M, Carpenter R, et al.
Nat Rev Drug Discov
. 2017 Dec;
17(4):280-299.
PMID: 29217836
Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of...
6.
Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann W, Cherubini M, et al.
J Neurodev Disord
. 2017 Jun;
9:3.
PMID: 28616094
Background: Arbaclofen improved multiple abnormal phenotypes in animal models of fragile X syndrome (FXS) and showed promising results in a phase 2 clinical study. The objective of the study is...
7.
Veenstra-VanderWeele J, Cook E, King B, Zarevics P, Cherubini M, Walton-Bowen K, et al.
Neuropsychopharmacology
. 2016 Oct;
42(7):1390-1398.
PMID: 27748740
Several lines of emerging data point to an imbalance between neuronal excitation and inhibition in at least a subgroup of individuals with autism spectrum disorder (ASD), including in those with...
8.
Erickson C, Veenstra-VanderWeele J, Melmed R, McCracken J, Ginsberg L, Sikich L, et al.
J Autism Dev Disord
. 2013 Nov;
44(4):958-64.
PMID: 24272415
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated...
9.
Henderson C, Wijetunge L, Kinoshita M, Shumway M, Hammond R, Postma F, et al.
Sci Transl Med
. 2012 Sep;
4(152):152ra128.
PMID: 22993295
Fragile X syndrome (FXS), the most common inherited cause of intellectual disability and autism, results from the transcriptional silencing of FMR1 and loss of the mRNA translational repressor protein fragile...
10.
Berry-Kravis E, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, et al.
Sci Transl Med
. 2012 Sep;
4(152):152ra127.
PMID: 22993294
Research on animal models of fragile X syndrome suggests that STX209, a γ-aminobutyric acid type B (GABA(B)) agonist, might improve neurobehavioral function in affected patients. We evaluated whether STX209 improves...